These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24486397)

  • 1. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
    Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B
    Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone promotes alternative activation in human monocyte-derived macrophages.
    Łabuzek K; Liber S; Bułdak Ł; Machnik G; Liber J; Okopień B
    Pharmacol Rep; 2013; 65(1):226-34. PubMed ID: 23563043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition and augmentation of alternative macrophage activation by progesterone.
    Menzies FM; Henriquez FL; Alexander J; Roberts CW
    Immunology; 2011 Nov; 134(3):281-91. PubMed ID: 21977998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance.
    Wada T; Ishikawa A; Watanabe E; Nakamura Y; Aruga Y; Hasegawa H; Onogi Y; Honda H; Nagai Y; Takatsu K; Ishii Y; Sasahara M; Koya D; Tsuneki H; Sasaoka T
    J Endocrinol; 2017 Dec; 235(3):179-191. PubMed ID: 28855315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts.
    Kobayashi N; Yoshida K; Nakano S; Ohno T; Honda T; Tsubokou Y; Matsuoka H
    Hypertension; 2006 Apr; 47(4):671-9. PubMed ID: 16505212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of ezetimibe on classical and alternative activation pathways of monocytes/macrophages isolated from patients with hypercholesterolemia.
    Suchy D; Łabuzek K; Machnik G; Okopień B
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):733-42. PubMed ID: 24781446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
    Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
    Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
    Raz-Pasteur A; Gamliel-Lazarovich A; Coleman R; Keidar S
    J Cardiovasc Pharmacol; 2012 Dec; 60(6):508-12. PubMed ID: 23232789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
    Ye P; Yamashita T; Pollock DM; Sasano H; Rainey WE
    Horm Metab Res; 2009 Jan; 41(1):35-9. PubMed ID: 18819053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
    Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
    Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
    Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
    Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a new selective aldosterone receptor antagonist.
    Weinberger MH
    Drugs Today (Barc); 2004 Jun; 40(6):481-5. PubMed ID: 15349128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.